Abstract
Rectal adenocarcinomas is usually associated to a poorer outcome than colon cancers. In this study we analyzed the impact on overall survival of p53 and Bcl-2, evaluated by immunohistochemical techniques, in 126 advanced rectal cancer patients submitted to 5 fluorouracil based adjuvant therapy. Shorter overall survival was observed in patients bearing p53 positive and Bcl-2 negative tumors, although in multivariate analysis only p53 emerged as independent predictor of a worse outcome. These results seem to indicate that, in stage III-IV rectal cancer, p53 alterations may identify high risk patients to be enrolled in more aggressive and/or innovative adjuvant/neoadjuvant treatments.
Original language | English |
---|---|
Pages (from-to) | 11-14 |
Number of pages | 4 |
Journal | Journal of Chemotherapy |
Volume | 16 |
Issue number | SUPPL. 5 |
Publication status | Published - Nov 2004 |
Keywords
- Adjuvant therapy
- Advanced rectal cancer
- Bcl-2
- p53
- Prognosis
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)